Summary
This 8-K filing from Pfizer Inc. primarily concerns the post-retirement arrangements for its Executive Chairman, Ian C. Read, and a director transition related to the planned Upjohn-Mylan merger. Following his retirement as Executive Chairman, Mr. Read will enter into a one-year consulting agreement with Pfizer and the new entity, NewCo, effective January 1, 2020. This agreement aims to leverage his extensive experience during the critical separation and combination phases of the Upjohn business with Mylan N.V. The agreement includes a monthly fee and provisions for continuity and governance of the spun-off entity. Additionally, the filing announces that board member James M. Kilts will resign from Pfizer's Board of Directors upon joining the board of the combined Upjohn-Mylan entity, expected in mid-2020. These changes signal the ongoing strategic realignments within Pfizer, particularly the execution of its plan to separate and combine its Upjohn business with Mylan, and the related leadership transitions.
Key Highlights
- 1Ian C. Read, former Executive Chairman, will provide consulting services for one year post-retirement, starting January 1, 2020, to aid in the Upjohn business separation and combination with Mylan.
- 2Mr. Read's consulting role is valued at $100,000 per month and includes support for the Upjohn business, potential board service on the NewCo board, and general advisory capacity.
- 3The consulting agreement has provisions for early termination, including upon the successful completion of the Upjohn-Mylan transaction, and includes customary non-competition and confidentiality clauses.
- 4Director James M. Kilts will resign from Pfizer's Board of Directors to join the board of the new entity formed by the combination of Upjohn and Mylan.
- 5This transition supports the ongoing strategic plan to spin off and combine Pfizer's established medicines business (Upjohn) with Mylan N.V.
- 6The filing includes the Consulting Agreement as Exhibit 10.1 and a related press release as Exhibit 99.1.